|
[1]
|
国家卫健委官网[Z]. http://www.nhc.gov.cn/
|
|
[2]
|
世界卫生组织官网[Z]. https://www.who.int
|
|
[3]
|
巩玥, 史志祥, 陈菁, 等. 冠状病毒的研究现状[J]. 中国生物工程杂志, 2020, 40(Z1): 1-20.
|
|
[4]
|
中国疾病预防控制中心新型冠状病毒感染的肺炎疫情一级响应态势分析与风险评估组. 2019新型冠状病毒疫情进展和风险评估[Z]. 2020.
|
|
[5]
|
国家卫健委办公厅. 新型冠状病毒感染的肺炎诊疗方案(试行第七版) [S]. 2020.
|
|
[6]
|
Huang, C.L., Wang, Y.M., Li., X.W., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506. [Google Scholar] [CrossRef]
|
|
[7]
|
叶陈伟. 抗感冒药物成分的药理特征及其临床用药分析[J]. 临床合理用药杂志, 2016, 9(6C): 171-172.
|
|
[8]
|
庞文渊, 王乔羽, 赵志刚. 新型冠状病毒肺炎的药物治疗方案及研究进展[J]. 临床药物治疗杂志, 2020(2): 24-29.
|
|
[9]
|
Cao, B., Wang, Y., Wen, D., et al. (2020) A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. The New England Journal of Medicin, 382, 1787-1799. [Google Scholar] [CrossRef]
|
|
[10]
|
Dong, L.Y., Hu, S.S. and Gao, J.J. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19). Drug Discoveries & Therapeutics, 14, 58-60. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Gautret, P., Lagier, J.-C., Parola, P., et al. (2020) Hy-droxychloroquine and Azithromycin as a Treatment of COVID-19: Results of an Open-Label Non-Randomized Clinical Trial. International Journal of Antimicrobial Agents, 56, Article ID: 105949. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
凌云, 狄亚敏, 陆青青, 等. 流行性感冒的病原学特征及其药物治疗进展[J]. 解放军药学学报, 2018, 34(2): 63-68.
|
|
[13]
|
冯修武. 上呼吸道感染中微生态制剂的功效研究[J]. 临床医药文献电子杂志, 2015(7): 1228-1229.
|
|
[14]
|
于恺英, 石汉平. 《关于新型冠状病毒肺炎患者的医学营养治疗专家建议》解读[J]. 中华医学杂志, 2020(100): E005.
|